Sai Life Sciences Limited has announced its unaudited standalone financial results for the second quarter and half year ended September 30, 2026. The company reported a profit after tax of ₹960.13 million for the quarter, compared to ₹713.39 million in the previous year. For the six months ended September 30, 2026, the profit after tax stood at ₹1,673.52 million. The results also detail the appointment of new Senior Management Personnel and the allotment of equity shares under employee stock option plans.
Sai Life Sciences Reports Financial Results
Sai Life Sciences Limited has officially released its unaudited standalone financial results for the second quarter and the six-month period ending September 30, 2026. The company’s board of directors considered and approved these results during a meeting held on November 5, 2026.
Standalone Financial Performance
For the quarter ended September 30, 2026, the company reported a total income of ₹6,509.18 million, with a profit after tax of ₹960.13 million. This compares to a profit after tax of ₹713.39 million for the same period in the previous year. Earnings per share (basic) for the quarter stood at ₹4.52.
The six-month period ended September 30, 2026, saw total income of ₹12,011.90 million, resulting in a profit after tax of ₹1,673.52 million. The earnings per share (basic) for the six-month period were ₹7.89. These figures reflect the company’s financial performance against the backdrop of its ongoing operations and strategic initiatives.
Senior Management Appointments
As part of its organizational developments, the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of several individuals to Senior Management Personnel (SMP) positions. These appointments, effective from November 5, 2026, include Mr. Sidhartha Das as Senior Vice President & Head – Human Resources, Mr. Vijay Kumar Suthari as Vice President – Head Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President – Corporate Communications.
Equity Share Allotment
The company also reported the allotment of 27,005 and 81,000 fully paid-up equity shares. These allotments were made upon the exercise of options granted under the Employees Stock Option Plan 2008 (ESOP 2008) and the Management Employee Stock Option Plan 2018 (MESOP 2018), respectively. This allotment has led to an increase in the company’s issued, subscribed, and paid-up equity share capital.
Consolidated Financial Overview
In addition to the standalone results, the company also presented its unaudited consolidated financial results. For the second quarter ended September 30, 2026, the consolidated profit after tax was ₹983.17 million. The consolidated profit after tax for the six months ended September 30, 2026, was ₹1,716.02 million, with basic earnings per share at ₹8.09.
The consolidated financial statements reflect the performance of the company and its subsidiaries, including Sai Life Sciences Inc, USA; Sai Life Sciences GmBH, Germany; and Sai Life Pharma Private Limited, India. The group operates in a single segment, providing “Contract Research, Development and Manufacturing Services (CRDMO)”.
Source: BSE
